SCHEMBL6164638

SCHEMBL6164638

COC(=O)c1cccc(-c2cscn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.54
GABRG2 P18507 1/20 0.51
GABRB3 P28472 1/20 0.51
GABRA5 P31644 1/20 0.51
GABRA3 P34903 1/20 0.51
CDK8 P49336 1/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
ERN1 O75460 1/20 0.47
KDM5C P41229 2/20 0.47
KDM4E B2RXH2 1/20 0.47
KDM6B O15054 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM2A Q9Y2K7 1/20 0.47
KDM3A Q9Y4C1 1/20 0.47
NEK1 Q96PY6 4/20 0.46
AXL P30530 1/20 0.46
KDM4A O75164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4536161 0.85 TP53 (0.49) KAT6ACA12CA1CA2CA9
SCHEMBL3193132 0.83 ALDH1A1 (0.49) CA12CA1CA2CA9KDM4E
SCHEMBL7855714 0.83 KAT6A (0.54) KAT6ACDK8KDM5CKDM4AKDM4B
SCHEMBL1724613 0.82 KAT6A (0.60) KAT6ACDK8KDM5CKDM4CKDM4A
SCHEMBL31018816 0.81 KDM4A (0.67) KAT6AKDM5CKDM4AKDM4BKDM5B
SCHEMBL4079387 0.81 KDM4A (0.67) KAT6AKDM5CKDM4AKDM4BKDM5B
SCHEMBL24526738 0.80 ECE1 (0.40) KAT6ACA12CA1CA2CA9
SCHEMBL67941 0.79 CA12 (0.68) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL6647247 0.78 KAT6A (0.53) KAT6AKDM5CKDM4EKDM4AKDM4B
SCHEMBL27715902 0.77 CA12 (0.71) GABRG2GABRB3GABRA5GABRA3CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 KAT6A 3557/4885GABRG2 166/4885GABRB3 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.